![\"\"](\"https:\/\/www.insilens.com\/wp-content\/uploads\/2026\/09\/20260923_Roche_Ionis_Therapeutic_Indications-768x512.png\")
<\/p>\n<\/p>\n
Company<\/strong><\/p>\n Roche \/ Ionis<\/p>\n Event Type<\/strong><\/p>\n Clinical Trial Data Readout<\/p>\n Modality<\/strong><\/p>\n Antisense Oligonucleotide<\/p>\n Asset<\/strong><\/p>\n Sefaxersen<\/p>\n Target<\/strong><\/p>\n Complement Factor B<\/p>\n Disease Area<\/strong><\/p>\n Primary IgA Nephropathy<\/p>\n Roche and Ionis reported that the 459-patient randomized IMAgINATION Phase 3 trial met its prespecified 37-week proteinuria endpoint in primary IgA nephropathy. Monthly subcutaneous sefaxersen significantly reduced 24-hour urine protein-to-creatinine ratio versus placebo. The companies disclosed neither the numerical effect nor its uncertainty. The blinded trial continues to evaluate estimated glomerular filtration rate at Week 105.<\/p>\n Sefaxersen is a liver-directed antisense oligonucleotide designed to lower complement factor B synthesis, interrupting amplification of the alternative complement pathway in glomerular injury. Roche licensed the molecule from Ionis. The companies reported no new safety signal and a profile consistent with prior trials, without a detailed adverse-event table.<\/p>\n The 23 September release calls the proteinuria change clinically meaningful but does not disclose the magnitude, baseline balance, subgroup effects or formal multiplicity details. Full results are promised at a future congress. A lower urinary protein marker is not yet a demonstrated preservation of renal function.<\/p>\n Interpretation one is that sustained upstream factor B suppression reduces immune-mediated glomerular damage. A randomized prespecified surrogate result and earlier target engagement support this mechanism. Against it, effect size and background treatment balance are unavailable, and complement inhibition can create infection risks not resolved by qualitative safety language.<\/p>\n Interpretation two is that monthly self-administered antisense could compete with oral or injectable IgAN therapies through mechanism and convenience. This is plausible because hepatic antisense may sustain target suppression, but no head-to-head evidence establishes best-in-class activity. Diverse baseline risk, background renin-angiotensin and SGLT2 treatment, duration and reimbursement will shape relative benefit.<\/p>\n Upgrade evidence includes a large placebo-adjusted UPCR effect with narrow uncertainty, consistent subgroups, preserved Week 105 eGFR slope and quantified infection and hepatic safety. A small numeric effect, eGFR dissociation or clinically important infections would downgrade the interpretation.<\/p>\n IgA nephropathy involves immune-complex deposition and complement activation in glomeruli, causing proteinuria and progressive renal impairment. Factor B is required for alternative-pathway amplification. Sefaxersen binds factor B messenger RNA in liver cells and recruits RNase H-mediated degradation, aiming to reduce circulating factor B and downstream kidney inflammation.<\/p>\n This is a positive platform and clinical signal because a late-stage randomized trial met a prespecified endpoint for a complement-targeted antisense therapy. Inference: the kidney benefit could extend beyond proteinuria, but that claim awaits the continued blinded eGFR readout. Competitive rank cannot be assigned without numerical results.<\/p>\n Signal Importance: 5 of 5. Signal Direction: positive for the prespecified proteinuria result. Confidence in Facts: high for trial design and qualitative primary result. Confidence in Interpretation: moderate-low until effect size, safety detail and eGFR outcome become available.<\/p>\n","protected":false},"excerpt":{"rendered":" Roche and Ionis reported that the 459-patient randomized IMAgINATION Phase 3 trial met its prespecified 37-week proteinuria endpoint in primary IgA nephropathy. Monthly subcutaneous sefaxersen significantly reduced 24-hour urine protein-to-creatinine ratio versus placebo. The…<\/p>\n","protected":false},"author":1,"featured_media":3412,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[1,11,3],"tags":[47,14,25],"class_list":["post-3404","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-all-categories","category-clinical","category-therapeutic-indication","tag-iga-nephropathy","tag-ionis-pharmaceuticals","tag-roche"],"blocksy_meta":[],"_links":{"self":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3404","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=3404"}],"version-history":[{"count":2,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3404\/revisions"}],"predecessor-version":[{"id":3419,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/posts\/3404\/revisions\/3419"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=\/wp\/v2\/media\/3412"}],"wp:attachment":[{"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=3404"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=3404"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.insilens.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=3404"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}Summary<\/h4>\n
Deep Analysis<\/h4>\n
Company and Product Background<\/h4>\n
Signal Extraction<\/h4>\n
\n
InSilens Take<\/h4>\n
Signal Assessment<\/h4>\n